Partial Personalization of Medical Treatment Decisions: Adverse Effects and Possible Solutions

Christopher Weyant and Margaret L. Brandeau
Additional contact information
Christopher Weyant: Department of Management Science and Engineering, Stanford University, Stanford, CA, USA
Margaret L. Brandeau: Department of Management Science and Engineering, Stanford University, Stanford, CA, USA

Medical Decision Making, 2022, vol. 42, issue 1, 8-16

Abstract: Background Personalizing medical treatment decisions based on patient-specific risks and/or preferences can improve health outcomes. Decision makers frequently select treatments based on partial personalization (e.g., personalization based on risks but not preferences or vice versa) due to a lack of data about patient-specific risks and preferences. However, partially personalizing treatment decisions based on a subset of patient risks and/or preferences can result in worse population-level health outcomes than no personalization and can increase the variance of population-level health outcomes. Methods We develop a new method for partially personalizing treatment decisions that avoids these problems. Using a case study of antipsychotic treatment for schizophrenia, as well as 4 additional illustrative examples, we demonstrate the adverse effects and our method for avoiding them. Results For the schizophrenia treatment case study, using a previously proposed modeling approach for personalizing treatment decisions and using only a subset of patient preferences regarding treatment efficacy and side effects, mean population-level health outcomes decreased by 0.04 quality-adjusted life-years (QALYs; 95% credible interval [crI]: 0.02–0.06) per patient compared with no personalization. Using our new method and considering the same subset of patient preferences, mean population-level health outcomes increased by 0.01 QALYs (95% crI: 0.00–0.03) per patient as compared with no personalization, and the variance decreased. Limitations We assumed a linear and additive utility function. Conclusions Selecting personalized treatments for patients should be done in a way that does not decrease expected population-level health outcomes and does not increase their variance, thereby resulting in worse risk-adjusted, population-level health outcomes compared with treatment selection with no personalization. Our method can be used to ensure this, thereby helping patients realize the benefits of treatment personalization without the potential harms.

Keywords: Medical decision making; personalized medicine; schizophrenia (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X211013773 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:42:y:2022:i:1:p:8-16

DOI: 10.1177/0272989X211013773

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().